Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-10. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
=== U.S. Department of Agriculture === In 1905, Pennington worked for the U.S. Department of Agriculture Bureau of Chemistry, which later became the U.S. Food and Drug Administration. Her director at the Bureau of Chemistry, Harvey W. Wiley, encouraged her to apply for a position as chief of the newly created Food Research Laboratory, which had been established to enforce the Pure Food and Drug Act of 1906. She was submitted to the position under the name M.E. Pennington in order to hide her gender. She accepted the position in 1907 and became the first female lab chief. One of her major accomplishments was the development of standards for the safe processing of chickens raised for human consumption. She also served as head of an investigation of refrigerated boxcar design and served on Herbert Hoover's War Food Administration during World War I.
Chinampa – Chinampas, sometimes called "floating gardens," were highly productive agricultural systems developed in the Valley of Mexico. The Aztecs built and used them extensively for agriculture in and around the lakes of the Valley of Mexico. Chocolate – Produced from the seed of the tropical Theobroma cacao tree, cacao was first cultivated by the Olmec of Mesoamerica as early as 1900 BCE. The Maya and Aztec developed chocolate into a frothy ceremonial beverage. Chunkey – a Native American game where a person rolls a hoop covered in a leather strap framework and tries to hit it with spears or arrows. This may have inspired the sport of skeet shooting. Compass (possibly) – the Olmecs are known to have knowledge of magnetism. The discovery of a hematite artifact has led many experts to believe that Olmec invented the compass 1,000 years before the Chinese did, although some still are not convinced. Compulsory education – the Aztec Triple Alliance, which ruled from 1428 to 1521 CE, is considered to be the first state to implement a system of universal compulsory education. Corn beer – brewed in the Andes, it is of pre-Incan origin from the Wari culture. Cornmeal – an unsoaked meal (coarse flour) ground from dried maize. It is a common staple food, and is ground to fine, medium, and coarse consistencies. Cranberries – Native Americans were the first to domesticate and grow cranberries in the north east coast of the United States.
==== MeSH D13.570.583 – purine nucleosides ==== MeSH D13.570.583.138 – adenosine MeSH D13.570.583.138.025 – adenosine-5'-(n-ethylcarboxamide) MeSH D13.570.583.138.240 – s-adenosylhomocysteine MeSH D13.570.583.138.264 – s-adenosylmethionine MeSH D13.570.583.138.300 – 2-chloroadenosine MeSH D13.570.583.138.300.200 – cladribine MeSH D13.570.583.138.325 – deoxyadenosines MeSH D13.570.583.138.325.075 – cladribine MeSH D13.570.583.138.325.105 – dideoxyadenosine MeSH D13.570.583.138.325.800 – puromycin aminonucleoside MeSH D13.570.583.138.500 – isopentenyladenosine MeSH D13.570.583.138.630 – phenylisopropyladenosine MeSH D13.570.583.138.711 – puromycin MeSH D13.570.583.138.711.650 – puromycin aminonucleoside MeSH D13.570.583.138.900 – vidarabine MeSH D13.570.583.454 – guanosine MeSH D13.570.583.454.240 – deoxyguanosine MeSH D13.570.583.454.500 – nucleoside q MeSH D13.570.583.616 – inosine MeSH D13.570.583.616.130 – didanosine MeSH D13.570.583.616.450 – inosine pranobex MeSH D13.570.583.616.900 – thioinosine MeSH D13.570.583.616.900.500 – methylthioinosine MeSH D13.570.583.910 – tubercidin
Sources: en.wikipedia.org
By the mid-1900s, lichenologists were already exploiting chemical traits for classification—decades before such methods reached vascular plant taxonomy. Because many lichens synthesize distinctive secondary metabolites (specialized compounds including lichen products unique to these organisms), workers devised simple spot tests in which reagents applied to the thallus yield diagnostic colour changes. The technique dates to the 1860s, but by 1951, the tests were routine. Elke Mackenzie listed K (potassium hydroxide solution), C (sodium hypochlorite), and Pd (p-phenylenediamine) as key diagnostic reagents because species often differ in their colour reactions. For example, a yellow K reaction usually signals the presence of the common metabolite atranorin, whereas a deep-red Pd reaction suggests certain depsidones. The chemical toolbox expanded sharply with the adoption of thin-layer chromatography (TLC) in the late 1960s. Chicita F. Culberson's Chemical and Botanical Guide to Lichen Products (1969) laid out a reproducible protocol for separating trace compounds from minute thallus chips, making TLC profiles a standard component of species descriptions. David Hawksworth's 1976 synthesis went a step further by integrating metabolite patterns into family‑ and order‑level frameworks, demonstrating that chemistry could diagnose natural groups and foreshadowing the molecular phylogenies that would follow. Chemical tests revealed cryptic diversity beneath outwardly uniform lichens.
== Further reading == Luig, H.; Kellerer, A. M.; Griebel, J. R. (2011). "Radionuclides, 1. Introduction". Ullmann's Encyclopedia of Industrial Chemistry. doi:10.1002/14356007.a22_499.pub2. ISBN 978-3527306732.
In December 2019, the US Food and Drug Administration (FDA) announced that it learned that some metformin medicines manufactured outside the United States might contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA), classified as a probable human carcinogen, at low levels. Health Canada announced that it was assessing NDMA levels in metformin. The European Medicines Agency provided an update on NDMA in metformin. In February 2020, the FDA found NDMA levels in some tested metformin samples that did not exceed the acceptable daily intake. In February 2020, Health Canada announced a recall of Apotex immediate-release metformin, followed in March by recalls of Ranbaxy metformin and in March by Jamp metformin. In May 2020, the FDA asked five companies to voluntarily recall their sustained-release metformin products. The five companies were not named, but they were revealed to be Amneal Pharmaceuticals, Actavis Pharma, Apotex Corp, Lupin Pharma, and Marksans Pharma Limited in a letter sent to Valisure, the pharmacy that had first alerted the FDA to this contaminant in metformin via a Citizen Petition. In June 2020, the FDA posted its laboratory results showing NDMA amounts in metformin products it tested. It found NDMA in certain lots of ER metformin and is recommending companies recall lots with levels of NDMA above the acceptable intake limit of 96 nanograms per day. The FDA is also collaborating with international regulators to share testing results for metformin.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.